<DOC>
	<DOCNO>NCT00991354</DOCNO>
	<brief_summary>An effective vaccine may way stop HIV pandemic . The purpose study determine safety immune response DNA vaccine , PENNVAX-B without IL-12 adjuvant give use electroporation .</brief_summary>
	<brief_title>Safety Immune Response PENNVAX-B DNA Vaccine With Without IL-12 HIV-uninfected Adults</brief_title>
	<detailed_description>An effective safe vaccine must develop order halt HIV pandemic . The purpose study assess safety immune response HIV DNA vaccine , PENNVAX-B give without IL-12 adjuvant deliver via electroporation . Participants study randomly assign one three group visit study clinic 9 time 9 month . Group 1 enroll first . Participants group receive 3 mg PENNVAX-B placebo vaccine Months 0 , 1 , 3 . Once safety data examine Group 1 , Group 2 begin enrollment . Group 2 participant receive 3 mg PENNVAX-B vaccine plus 1 mg IL-12 adjuvant placebo Months 0 , 1 , 3 . Once Group 1 Group 2 safety data collect Group 3 begin enrollment . These participant also receive 3 mg PENNVAX-B vaccine plus 1 mg IL-12 adjuvant placebo Months 0 , 1 , 3 . At clinic visit participant physical exam blood urine collect . After receive study injection , participant observe clinic least 30 minute . In addition , participant ask monitor symptom 3 day injection .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>Access participate HVTN CRS willingness follow plan duration study Ability willingness provide inform consent Assessment understanding : volunteer demonstrate understand study Step Study result ; complete questionnaire prior first vaccination , verbal demonstration understand questionnaire item answer incorrectly Willing receive HIV test result Willingness discuss HIV infection risk , amenable risk reduction counseling , commit maintain behavior consistent low risk HIV exposure last require protocol clinic visit Assessed clinic staff `` low risk '' HIV infection basis behavior within 12 month prior enrollment Good general health show medical history , physical exam , screen laboratory test Certain laboratory value . Details criterion find protocol . Negative HIV1 2 blood test : US participant must negative FDAapproved enzyme immunoassay ( EIA ) . Negative Hepatitis B surface antigen ( HBsAg ) Negative antiHepatitis C virus antibody ( antiHCV ) , negative HCV polymerase chain reaction ( PCR ) antiHCV positive Volunteers born female : negative serum urine beta human chorionic gonadotropin ( Î²HCG ) pregnancy test perform prior vaccination day initial vaccination Reproductive status : A volunteer bear female must agree consistently use effective contraception least 21 day prior enrollment last require protocol clinic visit sexual activity could lead pregnancy , reproductive potential , sexually abstinent Volunteers born female must also agree seek pregnancy alternative method , artificial insemination vitro fertilization last require protocol clinic visit Exclusion criterion : Within 12 month prior enrollment : excessive daily alcohol use frequent binge drinking chronic marijuana abuse illicit drug use Within 12 month prior enrollment : history newly acquire diagnosed syphilis ; newly acquire gonorrhea , nongonococcal urethritis , herpes simplex virus type 2 ( HSV2 ) , chlamydia , pelvic inflammatory disease ( PID ) , trichomonas , mucopurulent cervicitis , epididymitis , proctitis , lymphogranuloma venereum , chancroid Untreated incompletely treat syphilis infection HIV vaccine ( ) receive prior HIV vaccine trial . For potential participant receive control/placebo HIV vaccine trial , documentation identity study control/placebo must provide HVTN 080 PSRT , determine eligibility casebycase basis . NonHIV experimental vaccine ( ) receive within last 5 year prior vaccine trial . Exceptions may make vaccine subsequently undergone licensure FDA receive control/placebo experimental vaccine trial . Immunosuppressive medication receive within 168 day first vaccination . ( Not exclude : [ 1 ] corticosteroid nasal spray allergic rhinitis ; [ 2 ] topical corticosteroid mild , uncomplicated dermatitis [ 3 ] oral/parenteral corticosteroid give nonchronic condition expect recur [ length therapy 10 day less completion least 30 day prior enrollment ] ) Blood product receive within 120 day first vaccination Immunoglobulin receive within 60 day first vaccination Live attenuate vaccine influenza vaccine receive within 30 day first vaccination schedule within 14 day injection Investigational research agent receive within 30 day first vaccination Intent participate another study investigational research agent plan duration HVTN 080 study Influenza vaccine vaccine live attenuate vaccine receive within 14 day prior first vaccination ( e.g. , tetanus , pneumococcal , Hepatitis A B , HPV ) Allergy treatment antigen injection within 30 day first vaccination schedule within 14 day first vaccination Current antituberculosis ( TB ) prophylaxis therapy Allergy amidetype local anesthetic Presence implant electronic medical device ( e.g. , pacemaker , implantable cardioverter defibrillator ) A history cardiac arrhythmia , e.g. , supraventricular tachycardia , atrial fibrillation , frequent ectopy exam . ( Not exclude : sinus arrhythmia ) Clinically significant medical condition , physical examination finding , clinically significant abnormal laboratory result , past medical history clinically significant implication current health . Any medical , psychiatric , occupational , condition , judgment investigator , would interfere , serve contraindication , protocol adherence , assessment safety reactogenicity , participant 's ability give inform consent Serious adverse reaction vaccine include anaphylaxis relate symptom hive , respiratory difficulty , angioedema , and/or abdominal pain . Autoimmune disease Immunodeficiency Asthma mild , wellcontrolled asthma . Diabetes mellitus type 1 type 2 , include case control diet alone . ( Not exclude : history isolate gestational diabetes . ) Thyroidectomy , thyroid disease require medication last 12 month Angioedema within last 3 year episodes consider serious require medication within last 2 year Hypertension BMI &gt; 30 kg/m2 Bleeding disorder diagnose doctor ( e.g. , factor deficiency , coagulopathy , platelet disorder require special precaution ) Malignancy ( Not exclude : participant surgical excision subsequent observation period investigator 's estimation reasonable assurance sustain cure unlikely recur period study . ) Seizure disorder Asplenia : condition result absence functional spleen Psychiatric condition precludes compliance protocol Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>